Glenmark Pharmaceuticals Share News - Latest Updates, Live News & More

More news about Glenmark Pharmaceuticals

Glenmark Pharma Secures $1.1 Billion Deal for HER2-Targeting Cancer Therapy

Glenmark Pharmaceuticals' subsidiary, Glenmark Specialty S.A., has entered into a $1.1 billion agreement with Hengrui Pharma for the exclusive rights to Trastuzumab Rezetecan, a next-generation HER2-targeting antibody drug conjugate. The deal includes an $18 million upfront payment, potential milestone payments of up to $1.09 billion, and royalties based on net sales. Glenmark gains worldwide rights to develop and commercialize the therapy, excluding specific regions like China, USA, Canada, and Europe. Trastuzumab Rezetecan has shown promising results in treating various cancers and has received approvals and designations in China and the USA.

22Sept 25

Glenmark Pharmaceuticals Revises Record Date to October 3, 2025 for Interim Dividend

Glenmark Pharmaceuticals has announced a new record date of October 3, 2025, for the payment of interim dividend for FY 2025-26. The company's board meeting to consider and approve the interim dividend remains scheduled for September 26, 2025. This revision was communicated to both BSE and NSE, aligning with SEBI regulations. Shareholders on record as of the new date will be eligible for the dividend if approved.

18Sept 25

Glenmark Pharma Inks Deal with Astria Therapeutics for Monoclonal Antibody Development

Glenmark Pharmaceuticals has signed a partnership agreement with Astria Therapeutics to develop monoclonal antibodies. Astria Therapeutics reported encouraging initial results from its Phase 1A clinical trial of STAR 0310. This collaboration aims to leverage both companies' expertise in monoclonal antibody development, potentially leading to innovative therapeutic solutions. The partnership could strengthen Glenmark's position in the rapidly growing monoclonal antibody market, which has applications in treating various diseases including certain cancers and autoimmune disorders.

15Sept 25

Glenmark Pharmaceuticals to Transfer Consumer Care Business to Wholly Owned Subsidiary

Glenmark Pharmaceuticals has executed a Business Transfer Agreement to shift its Consumer Care business to Glenmark Consumer Care Limited, a wholly owned subsidiary. The agreement was signed on September 15, 2025, with the transaction expected to complete by December 31, 2025, subject to conditions. This follows an earlier announcement on August 14, 2025. The company has informed stock exchanges about this development in compliance with regulatory requirements.

09Sept 25

Glenmark Pharma's Subsidiary IGI Secures $700 Million Upfront Payment from AbbVie in Landmark Licensing Deal

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has received a $700 million upfront payment from AbbVie as part of an exclusive global licensing agreement for IGI's lead investigational asset, ISB 2001. The deal covers North America, Europe, Japan, and Greater China markets. Glenmark confirmed the payment receipt in a stock exchange filing, adhering to contractual terms. The company also announced upcoming analyst and investor meetings in Singapore, stating no unpublished price-sensitive information would be shared.

05Sept 25

Glenmark Pharmaceuticals: Advances in Lung Cancer Treatment and Allergy Relief

Glenmark Pharmaceuticals has initiated a global Phase 3 trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, for resectable Stage III Non-Small Cell Lung Cancer. The trial has received approval from DCGI for patient enrollment in India, with plans to expand to Russia, Brazil, and Mexico. Additionally, Health Canada has approved RYALTRIS, a nasal spray developed by Glenmark and Bausch Health, for treating moderate to severe seasonal allergic rhinitis in patients 6 years and older.

03Sept 25

Glenmark Pharma: Potential GST Exemption on Cancer Drugs and New Product Launch

Glenmark Pharmaceuticals faces two significant developments: a potential GST exemption for cancer medications in India and the launch of Eribulin Mesylate Injection in the US. The GST exemption could reduce cancer treatment costs and impact pricing strategies. Glenmark's US subsidiary will launch Eribulin Mesylate Injection, bioequivalent to Halaven® Injection, in September 2025. The Halaven® market had annual sales of $66.30 million for the 12-month period ending July 2025. This launch marks Glenmark's first complex generic in their portfolio, reinforcing their commitment to the institutional channel.

02Sept 25

Glenmark Pharma Set to Launch Eribulin Mesylate Injection in U.S. Market

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Limited, is set to introduce Eribulin Mesylate Injection in the U.S. market. The product is bioequivalent to Eisai Inc.'s Halaven® Injection, which had annual sales of $66.30 million. Distribution will begin in September 2025, marking Glenmark's entry into complex generics and expanding its presence in the oncology segment.

19Aug 25

Glenmark Pharma Targets 19-20% Ebitda Margin in FY26, Plans US Launch of Micafungin Injection

Glenmark Pharmaceuticals maintains its FY26 guidance of 10-12% revenue growth and 19-20% Ebitda margin. The company's Q1 consolidated revenue increased by 0.60% to Rs 3,264.40 crore. European business shows over 25% CAGR for three years, while US business grew 9% quarter-on-quarter in Q1. Mycamine for Injection achieved annual sales of $60.70 million. Glenmark's US division plans to launch Micafungin Injection in 50 mg and 100 mg formulations.

14Aug 25

Glenmark Pharma Projects Strong Growth in Europe and Emerging Markets, Reports Q1 FY26 Results

Glenmark Pharmaceuticals announced its Q1 FY26 financial results with consolidated revenue of Rs. 32,644.00 Mn, up 0.60% YoY. The company expects double-digit growth in Europe and emerging markets from Q2 FY26. Key highlights include EBITDA of Rs. 5,805.00 Mn and adjusted PAT of Rs. 3,129.00 Mn. The India business grew by 3.70% YoY, while North America saw an 8.90% quarter-on-quarter increase. Glenmark settled an antitrust lawsuit in the US for $37.75 million, which was provisioned in Q1 results. The company remains focused on driving growth across markets and advancing its product portfolio.

24Jul 25

Glenmark Pharma Faces FDA Warning for Pithampur Plant Amid Positive Credit Outlook

Glenmark Pharmaceuticals received an FDA Warning Letter for its Pithampur facility due to CGMP non-compliance. The FDA recommended engaging a CGMP consultant and reviewing global quality systems. Despite this, India Ratings revised Glenmark's long-term bank facilities outlook to Positive from Stable, affirming 'IND AA' rating. This positive outlook stems from a licensing agreement between Glenmark's subsidiary and AbbVie Inc., potentially yielding significant financial gains. Glenmark's financials show improvement with 12.80% YoY revenue growth and expanded EBITDA margin. The company's stock remains resilient, trading 0.48% higher at ₹2149.00, with a 33.00% gain.

23Jul 25

Glenmark Pharmaceuticals Outlook Revised to Positive on AbbVie Licensing Deal

India Ratings and Research revised Glenmark Pharmaceuticals Limited's (GPL) outlook to Positive from Stable, affirming 'IND AA' rating. This follows a significant licensing agreement between GPL's subsidiary and AbbVie Inc. for ISB 2001, potentially worth up to $1.925 billion. GPL reported strong financial results with 12.80% revenue growth and improved EBITDA margin. The India business grew 31.90%, while the US business declined slightly. GPL faces ongoing regulatory challenges with USFDA observations. Future outlook remains positive with expected revenue growth and margin expansion.

22Jul 25

Glenmark Pharmaceuticals Executes Rs. 28.84 Crore Block Trade on NSE

A significant block trade of 133,579 shares of Glenmark Pharmaceuticals occurred on the National Stock Exchange (NSE), valued at Rs. 28.84 crores. The shares were traded at Rs. 2,158.70 each. This transaction demonstrates market liquidity and potential investor confidence in the company. Glenmark Pharmaceuticals is known for its global presence in various therapeutic areas including dermatology, respiratory, and oncology.

17Jul 25

S&P: Glenmark Pharma Set to Become Net Cash Positive Following AbbVie Licensing Agreement

S&P Global Ratings reports that Glenmark Pharmaceuticals' licensing agreement with AbbVie for ISB 2001 is expected to significantly improve the company's financial position. The deal could make Glenmark net cash positive, reducing adjusted debt to 10-11 billion rupees by fiscal 2026. S&P projects 10% revenue growth for Glenmark in fiscal 2026, followed by 9-11% annual growth for the next three years, with stable EBITDA margins.

17Jul 25

Glenmark Pharma Unveils Strategic Transformation Plan at Investor Day 2025

Glenmark Pharmaceuticals presented its 'Glenmark 3.0' strategic roadmap at Investor Day 2025 in Mumbai. The plan focuses on transforming into a research-led global pharmaceutical player, emphasizing three key therapeutic areas: Dermatology, Respiratory, and Oncology. With a current revenue of $1.60 billion and presence in over 80 countries, Glenmark aims to capitalize on branded markets and continue its innovation in NCE and NBE research. The company plans to maintain financial discipline while investing in growth opportunities and advancing its innovative pipeline, particularly in oncology and immunology through its BEAT® protein platform.

16Jul 25

Glenmark Pharma Unveils Ambitious Global Expansion Strategy at Investor Day 2025

Glenmark Pharmaceuticals presented its 'Glenmark 3.0' strategy at its Investor Day 2025 in Mumbai. The plan focuses on becoming a global leader in Dermatology, Respiratory, and Oncology. Key goals include expanding branded and specialty products, leveraging biotech innovation through Ichnos Glenmark Innovation, and targeting sustainable growth in key areas. The company aims to increase branded market revenue contribution to over 70% by FY30. Financial targets include 12-14% CAGR revenue growth, 23% consolidated EBITDA margin, and maintaining 20% ROCE and ROE. Glenmark reported ₹135 billion revenue for FY2025 and operates in over 80 countries.

14Jul 25

Glenmark Pharma Receives FDA Warning Letter for Indore Facility, No Disruptions Expected

Glenmark Pharmaceuticals has received a warning letter from the U.S. FDA regarding its manufacturing facility in Indore, Madhya Pradesh. The company assures that no data integrity issues were identified during the inspection and expects no disruptions to its supply chain or revenue streams. Glenmark will likely work with the FDA to address the concerns and implement necessary corrective actions.

14Jul 25

Glenmark Pharmaceuticals Faces USFDA Warning, Inks Licensing Deal with AbbVie

Glenmark Pharmaceuticals received a USFDA warning letter for its Indore facility following a February inspection, but assures no impact on existing revenue or supply chain. Simultaneously, Glenmark's subsidiary entered a licensing agreement with AbbVie for ISB-2001, retaining rights in India and emerging markets. The company faces regulatory challenges while pursuing business expansion through strategic partnerships.

10Jul 25

Glenmark Pharma's Subsidiary IGI Inks $700 Million Licensing Deal with AbbVie for Novel Cancer Drug

Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharmaceuticals, has signed a global licensing agreement with AbbVie for ISB 2001, a promising cancer treatment. The deal is worth up to $1.93 billion, including a $700 million upfront payment and potential milestone payments of $1.23 billion. ISB 2001, a trispecific T-cell engager for relapsed/refractory multiple myeloma, has shown an overall response rate of 79% in Phase 1 trials. AbbVie gains exclusive rights in major markets, while Glenmark retains rights in emerging markets. The drug has received Orphan Drug and Fast Track Designations from the U.S. FDA.

24Jun 25

Glenmark Pharmaceuticals Enters Immune-Oncology Market with Launch of Lung Cancer Drug Tevimbra

Glenmark Pharmaceuticals has introduced Tevimbra, a new lung cancer treatment drug, in the Indian market. Approved by CDSCO, Tevimbra is indicated for non-small cell lung cancer and oesophageal squamous cell carcinoma. This launch marks Glenmark's entry into the immune-oncology space in India, expanding treatment options for cancer patients. The drug, developed by BeiGene, is approved for both first-line and second-line treatment of NSCLC.

24Jun 25

Glenmark Pharmaceuticals Expands Cancer Treatment Portfolio with Tevimbra® Launch in India

Glenmark Pharmaceuticals has introduced Tevimbra®, an immuno-oncology medicine, to the Indian market. The drug is designed to treat Non-Small Cell Lung Cancer (NSCLC) and Esophageal Squamous Cell Carcinoma (ESCC). This launch expands advanced cancer treatment options in India, potentially improving patient outcomes and increasing access to innovative therapies.

18Jun 25

Glenmark Pharma's Monroe Facility Passes USFDA Inspection with Minor Observations

Glenmark Pharmaceuticals' Monroe facility underwent a USFDA inspection resulting in five procedural observations with no data integrity concerns. This outcome is viewed positively, suggesting robust quality control and data management practices. The facility is likely to continue operations without significant disruptions, pending resolution of the minor observations.

09Jun 25

Glenmark Pharmaceuticals Expands Cancer Treatment Options with Brukinsa Launch in India

Glenmark Pharmaceuticals has introduced Brukinsa, a new drug for blood cancer treatment, to the Indian market. The Drug Controller General of India (DCGI) has approved Brukinsa, which is a Bruton's tyrosine kinase (BTK) inhibitor designed to target and block the BTK protein. This launch aims to expand treatment options for blood cancer patients in India, providing oncologists with an additional tool against B-cell malignancies such as lymphomas and leukemias.

02Jun 25

Glenmark Pharma Reports Promising Results for Novel Multiple Myeloma Treatment

Glenmark Pharmaceuticals has reported positive results from the full dose-escalation study of ISB 2001, a novel BCMA × CD38 × CD3 trispecific antibody for relapsed/refractory multiple myeloma. The treatment demonstrated high response rates and a favorable safety profile. ISB 2001, a first-in-class therapy, targets three proteins simultaneously: BCMA, CD38, and CD3, potentially offering a new approach for patients resistant to existing therapies. The study showed strong efficacy across various dose levels and a manageable safety profile. Further clinical trials are expected to gather more comprehensive data for potential regulatory approvals.

02Jun 25

Glenmark's Multiple Myeloma Drug Shows Promising Results in Early-Stage Trial

Glenmark Pharmaceuticals' drug ISB 2001 for multiple myeloma demonstrated a 79% overall response rate in an early-stage clinical trial for relapsed/refractory cases. The drug showed manageable side effects in heavily pre-treated patients. The U.S. FDA has granted fast track designation to ISB 2001, potentially expediting its development and review process.

27May 25

Glenmark Pharmaceuticals: ICICI Securities Raises Target Price, Maintains 'Reduce' Rating

Glenmark Pharmaceuticals plans to launch gFlovent in the US market by Q2 FY26 and anticipates a re-inspection of its Monroe plant. The company faces challenges in India due to product discontinuations but expects significant revenue from out-licensing ISB 2001 in FY26. ICICI Securities maintains a 'Reduce' rating while raising the target price.

27May 25

Glenmark Pharma Unveils Product Launch Pipeline and FY26 Financial Projections

Glenmark Pharmaceuticals has announced key product launches and financial projections for FY26. The company secured UK approval for Winlevi, plans to launch two oncology products (Tislelizumab and Zanubrutinib) in partnership with BeiGene, and expects to introduce new respiratory products. Glenmark's partner in mainland China anticipates product approval in FY26. The company projects 10-12% revenue growth, 19-20% EBITDA margin, and ₹300-400 crore cash generation for FY26.

26May 25

Glenmark Pharmaceuticals: Q4 Results Miss Estimates, Shares Slump

Glenmark Pharmaceuticals reported Q4 results below market expectations. Revenue increased 6.30% YoY to Rs 3,256.00 crore and EBITDA grew 11.00% to Rs 561.00 crore, both missing Bloomberg estimates. Net profit stood at Rs 4.70 crore, significantly lower than the estimated Rs 344.00 crore. Following the results, the company's shares fell by 3.53%.

23May 25

Glenmark Pharmaceuticals: Q4 Profit Misses Estimates, Declares Dividend

Glenmark Pharmaceuticals reported Q4 FY23 results with a consolidated net profit of ₹4.70 crore, turning profitable from a loss last year but falling short of expectations. Revenue increased by 6.3% to ₹3,256.00 crore, while EBITDA rose 11% to ₹561.00 crore. The company declared a dividend of ₹2.50 per equity share.

09May 25

Glenmark Pharma's Indore Facility Faces USFDA Compliance Challenge

Glenmark Pharmaceuticals' Indore manufacturing facility has been classified as 'Official Action Indicated' (OAI) by the U.S. Food and Drug Administration following a February 2025 inspection. This status suggests potential violations of regulatory standards and may affect new product approvals. Glenmark has committed to addressing the USFDA's concerns and working towards full compliance. The company may face increased scrutiny and need to implement significant operational changes.

06May 25

Glenmark's Subsidiary Secures FDA Fast Track Designation for Novel Multiple Myeloma Treatment

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has received FDA Fast Track Designation for ISB 2001, a novel trispecific antibody therapeutic for relapsed or refractory multiple myeloma. The drug, currently in Phase 1 trials, has shown promising initial results with high overall response rates and a favorable safety profile. This designation could expedite the drug's development and review process, addressing a significant unmet need in multiple myeloma treatment.

05May 25

Glenmark's Subsidiary Secures FDA Fast Track Designation for Multiple Myeloma Drug

Glenmark Pharmaceuticals' subsidiary, Ichnos Glenmark Innovation (IGI), has received Fast Track Designation from the FDA for ISB 2001, a tri-specific antibody therapeutic for relapsed/refractory multiple myeloma. The drug showed promising Phase 1 results and previously received orphan drug designation. This status allows for expedited review and development, potentially leading to earlier approval. Complete results are expected at the 2025 ASCO annual meeting.

30Apr 25

Glenmark Pharma Refutes Connection to Flagged Drugs, Confirms Products as Spurious

Glenmark Pharmaceuticals has issued a strong clarification regarding recent reports about drugs flagged by the Central Drugs Standard Control Organisation (CDSCO). The company states that the products in question are spurious and were not manufactured by Glenmark or its affiliates. Regulatory authorities have confirmed these items as counterfeit. Glenmark is taking steps to counter spurious products, including changes in packaging and strengthening the supply chain.

21Apr 25

Glenmark Pharmaceuticals Witnesses Significant Block Trade on NSE

A significant block trade of 208,684 Glenmark Pharmaceuticals shares occurred on the National Stock Exchange (NSE) at Rs. 1,350.60 per share, totaling Rs. 28.18 crores. The identities of the buyer and seller were not disclosed. This large transaction has drawn market attention, potentially signaling shifts in investor sentiment or portfolio adjustments by major players in the pharmaceutical sector.

17Apr 25

Glenmark Pharmaceuticals: US Arm to Launch $422 Million ADHD Drug in 2025

Glenmark Pharmaceuticals Inc., USA plans to introduce generic versions of Adderall tablets in the US market starting May 2025. The generic drug, available in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths, aims to address the current shortage of ADHD medication. The Adderall tablets market had annual sales of approximately $421.70 million for the 12-month period ending February 2025. Glenmark's entry is expected to increase accessibility, potentially reduce costs, and help alleviate the shortage of this widely prescribed medication.

16Apr 25

Glenmark Pharmaceuticals Set to Launch Generic Adderall in US Market

Glenmark Pharmaceuticals plans to introduce a generic version of Adderall tablets in the United States through its US subsidiary. The product, available in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths, is bioequivalent to Teva's Adderall® Tablets. With annual sales of $421.70 million for Adderall® Tablets, Glenmark aims to capitalize on this market opportunity. The company plans to begin distribution in May 2025, potentially alleviating ongoing shortages in the country.

09Apr 25

Glenmark Pharmaceuticals Faces FDA Recall of 39 Products in US Market

The US FDA has initiated a Class-II recall of 39 drugs from Glenmark Pharmaceuticals' US arm due to nearing expiry dates. Most affected products were manufactured at Glenmark's Pithampur plant. The recall, classified in April 2025, led to a 7% drop in Glenmark's stock price. This event poses financial, regulatory, and reputational challenges for the company, highlighting the ongoing scrutiny faced by Indian pharmaceutical firms in international markets.

07Apr 25

Glenmark Pharmaceuticals Announces Key Leadership Changes: Anurag Mantri Appointed as President

Glenmark Pharmaceuticals has appointed Anurag Mantri as President, effective April 7, 2025. Mantri, with over 30 years of management experience, joins from Jindal Stainless Limited. V.S. Mani, current Executive Director & Global CFO, will retire early, stepping down on May 26, 2025. Mantri is expected to assume Mani's roles pending approval from relevant committees and the Board.

01Apr 25

Glenmark Pharma Launches Vancomycin Injection in USA, Plans to Shut Down Swiss Facility

Glenmark Pharmaceuticals has launched Vancomycin Hydrochloride for Injection USP in the USA, a product with annual sales of $39.30 million. Simultaneously, the company is closing its Chemistry, Manufacturing, and Controls (CMC) development and clinical supplies manufacturing facility in La Chaux-de-Fonds, Switzerland.

29Mar 25

Glenmark Pharma to Shut Down Swiss Subsidiary's CMC and Clinical Supplies Operations

Glenmark Pharmaceuticals announced the closure of its Swiss subsidiary IGI Inc.'s Chemistry, Manufacturing, and Controls (CMC) development and clinical supplies manufacturing operations in La Chaux-de-Fonds by July 31, 2025. The facility, valued at Rs. 223.52 million, was used for captive consumption and its closure is not expected to impact the company's turnover. Glenmark plans to shift these operations to Contract Development and Manufacturing Organizations (CDMOs) to meet future clinical program demands. This strategic move is not anticipated to adversely affect Glenmark's consolidated financials.

24Mar 25

USFDA Flags Issues at Glenmark Pharmaceuticals' Indian Manufacturing Facility

The USFDA has identified problems at a Glenmark Pharmaceuticals factory in India, potentially impacting the quality and supply of certain generic medications in the US market. This development could lead to increased regulatory scrutiny, possible delays in new product approvals, and the need for corrective actions by Glenmark. The situation highlights the importance of quality control in pharmaceutical manufacturing and may have broader implications for the generic drug industry.

21Mar 25

Glenmark Pharma Secures ANDA Approval for OTC Olopatadine Eye Drops

Glenmark Pharmaceuticals has received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), bioequivalent to Alcon's Pataday® Once Daily Relief. The product enters a market with annual sales of $50.70 million. Glenmark Therapeutics Inc., USA will distribute the eye drops in the United States, strengthening the company's position in the OTC eye care market.

20Mar 25

Glenmark Pharmaceuticals Secures FDA Approval for OTC Olopatadine Ophthalmic Solution

Glenmark Pharmaceuticals' US subsidiary has received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), an over-the-counter eye drop solution. The product is bioequivalent to Alcon's Pataday® Once Daily Relief Ophthalmic Solution, which had annual sales of $50.70 million. Glenmark Therapeutics Inc., USA will distribute the product in the US market, expanding the company's OTC ophthalmic portfolio.

20Mar 25

Glenmark Pharma Secures ANDA Approval for OTC Olopatadine Eye Drops, Tapping into $50.70 Million Market

Glenmark Pharmaceuticals' U.S. subsidiary has received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). This eye drop solution is bioequivalent to Alcon's Pataday® Once Daily Relief, which had annual sales of $50.70 million. Glenmark Therapeutics Inc., USA will distribute the product in the United States, strengthening the company's presence in the OTC ophthalmic market.

12Mar 25

Glenmark Pharma Bolsters Cardiometabolic Portfolio with Empagliflozin Launch in India

Glenmark Pharmaceuticals has introduced three new products under its 'Glempa' brand, featuring Empagliflozin and its combinations, aimed at treating type 2 diabetes mellitus and heart failure. The launch includes Glempa (Empagliflozin), Glempa-L (Empagliflozin + Linagliptin), and Glempa-M (Empagliflozin + Metformin). Clinical trials have shown significant benefits in cardiovascular risk reduction, glycemic control, and weight management. The Empagliflozin market in India is valued at ₹642 crore, while the entire SGLT2 inhibitors market stands at ₹2,904 crore.

10Mar 25

Glenmark Therapeutics Enters $555 Million OTC Market with New Polyethylene Glycol Solution

Glenmark Pharmaceuticals' US subsidiary has launched Polyethylene Glycol 3350, Powder for Solution, in a 17 grams per capful dosage. This product enters a market segment with annual sales of approximately $555.7 million, competing with MiraLAX®. The launch aligns with Glenmark's strategy to expand its OTC portfolio and meet market demands in the US pharmaceutical sector.

04Mar 25

Glenmark Pharmaceuticals USA Expands Portfolio with Acetylcysteine Injection Launch

Glenmark Pharmaceuticals Inc., USA has acquired and launched Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials in the U.S. market. The product's market achieved annual sales of approximately $15.2 million for the 12-month period ending January 2025. Glenmark acquired the ANDA from Aspen Pharma USA Inc. This strategic move aims to strengthen Glenmark's position in the U.S. hospital segment.

02Mar 25

Glenmark Pharmaceuticals Initiates Massive Recall of ADHD Medication in US Market

Glenmark Pharmaceuticals has initiated a recall of approximately 1.5 million bottles of Atomoxetine Capsules, a generic ADHD medication, from the US market. The recall, which began on January 29, 2025, affects multiple strengths ranging from 10 mg to 100 mg. The action is due to the presence of N-Nitroso Atomoxetine impurity above FDA-recommended limits. This large-scale recall raises concerns about quality control processes and may have significant financial implications for the company, including recall costs, potential sales losses, and possible expenses for manufacturing improvements.

27Feb 25

Glenmark Pharmaceuticals Launches Epinephrine Injection in US Market, Targeting $42.7 Million Opportunity

Glenmark Pharmaceuticals' US subsidiary has launched Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial in the US market on February 27, 2025. The product is bioequivalent to BPI Labs' reference drug and enters a market with annual sales of $42.7 million. Glenmark has secured 180 days of Competitive Generic Therapy exclusivity, potentially giving it a significant market advantage.

24Feb 25

Glenmark Pharmaceuticals Settles Antitrust Lawsuits for $7 Million

Glenmark Pharmaceuticals has agreed to pay $7 million to settle antitrust and consumer protection lawsuits filed by Humana, Centene, and Kaiser. The lawsuits alleged anti-competitive agreements related to generic versions of cholesterol-lowering drugs Zetia® and Vytorin®. Glenmark denies all allegations, stating the settlement is not an admission of liability. This settlement follows earlier agreements reached in 2023 with other plaintiff groups.

24Feb 25

Glenmark Pharma Settles Antitrust Lawsuits for $7 Million with Major Healthcare Companies

Glenmark Pharmaceuticals has reached a $7 million settlement with Humana, Centene, and Kaiser to resolve antitrust and consumer protection lawsuits related to cholesterol drugs Zetia® and Vytorin®. The settlement, approximately ₹58.1 crore, concludes long-standing legal disputes consolidated in the Eastern District of Virginia, U.S. Glenmark denies all allegations and maintains that the settlement does not imply admission of liability or illegality. This agreement follows previous settlements with other plaintiff groups in 2023.